Jiangsu HengRui Medicine Co., Ltd.
104 active trials across 15 therapeutic areas
104
Active Trials
41
Phase 1
50
Phase 2
35
Phase 3
15
Therapeutic Areas
Portfolio Concentration: 66% of active trials in Oncology
Oncology
69 active / 168 total
Solid Tumor (Advanced)
22 active
51 total since 2015
Prostate Cancer
12 active
4 Ph3
20 total since 2015
Breast Cancer
9 active
5 Ph3
16 total since 2015
NSCLC
3 active
1 Ph3
10 total since 2015
Pancreatic Cancer
3 active
3 Ph3
8 total since 2015
Gastric Cancer
3 active
2 Ph3
6 total since 2015
Lung Cancer (General)
3 active
1 Ph3
6 total since 2015
Non-Hodgkin Lymphoma
3 active
5 total since 2015
Neuroendocrine Tumors
3 active
2 Ph3
3 total since 2015
Hepatocellular Carcinoma
2 active
2 Ph3
7 total since 2015
Cervical Cancer
2 active
1 Ph3
3 total since 2015
Ovarian Cancer
1 active
1 Ph3
6 total since 2015
Colorectal Cancer
1 active
1 Ph3
4 total since 2015
Cholangiocarcinoma
1 active
3 total since 2015
HER2+ Breast Cancer
1 active
1 Ph3
2 total since 2015
Esophageal Cancer
0 active
4 total since 2015
Triple Negative Breast Cancer
0 active
4 total since 2015
ALL
0 active
3 total since 2015
SCLC
0 active
2 total since 2015
Sarcoma
0 active
1 total since 2015
Hodgkin Lymphoma
0 active
1 total since 2015
AML
0 active
1 total since 2015
MDS
0 active
1 total since 2015
Melanoma
0 active
1 total since 2015
Metabolic
8 active / 28 total
Immunology
4 active / 27 total
Rare Disease
4 active / 9 total
Musculoskeletal
2 active / 15 total
Cardiovascular
2 active / 11 total
Respiratory
2 active / 5 total
Dermatology
2 active / 2 total
CNS
1 active / 4 total
Pain
0 active / 8 total
Urology
0 active / 7 total
Infectious Disease
0 active / 4 total
Women's Health
0 active / 3 total
Ophthalmology
0 active / 2 total
Renal
0 active / 2 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)